查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2151718

用於藥物篩檢和評估的小鼠模型市場：全球市場預測，2026-2032年

Mouse Model for Drug Screening & Evaluation Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，「用於藥物發現篩檢和評估的小鼠模型」市場將成長至 119,864 億美元，複合年成長率為 7.32%。

主要市場統計數據
基準年 2025 730,880,000 美元
預計年份：2026年 7.846億美元
預測年份 2032 1,198,640,000 美元
複合年成長率 (%) 7.32%

小鼠模型是轉化藥物篩檢和評估的基礎。

在進行人體研究之前，小鼠模型仍然是評估藥理學、毒理學、療效、疾病機制和生物標記關係的重要工具。其價值在於將可控的遺傳因素和環境與可測量的生理和行為終點結合。然而，解讀研究結果需要考慮物種差異、模型特異性限制以及與人類相關的補充方法。有效的研究方案擴大將小鼠研究視為綜合檢驗的一部分，而非獨立的驗證手段。

轉化研究的嚴謹性和模型的多樣性正在改變臨床前研究的進行方式。

研究趨勢正從廣泛依賴傳統近交系小鼠轉向採用一系列針對特定目的的模型。這些模型包括基因改造小鼠、人源化系統、免疫力缺乏宿主、患者來源的異質骨移植模型，以及性別、年齡和合併症多樣性模型，能夠解決傳統研究設計無法涵蓋的問題。同時，由於研究註冊、隨機化、盲法、統計功效計算和獨立重複性等方面的改進，人們對研究結果的可重複性要求也越來越高。

人工智慧加速設計、分析和翻譯。

人工智慧正日益廣泛地應用於實驗模型選擇、化合物優先排序、影像分析、表現型分類以及識別多模態資料集之間的關係。電腦視覺有助於更一致地評估腫瘤負荷、組織病理學、運動性、行為和細胞反應，而機器學習工作流程可以整合分子、臨床和臨床前訊息，從而改善假設生成。

區域優先事項反映了不同的研究基礎設施和法規環境。

在北美，先進的生物醫學基礎設施、轉化研究領域的夥伴關係以及對可重複性的高度重視，正在推動基因改造小鼠、人源化小鼠、成像技術和數據豐富的鼠類研究的發展。同時，在拉丁美洲，專業設施取得的差異、學術界和公共部門研究能力的提升，以及可擴展方案的重要性、區域疾病控制重點和合作研究平台，正在塑造該地區的研究格局。

國際組織正在塑造合作、標準和研究成果獲取途徑。

東南亞國協可受益於共用的基礎設施、協調一致的培訓和區域研究網路，以應對感染疾病、代謝紊亂和區域特有疾病。金磚國家之間的合作，只要數據標準和倫理監管保持一致，就能擴大研究能力的取得途徑，加強比較研究，並支持針對不同族群的模式開發。

每個國家在轉化研究的規模、專業化程度和優先事項方面的能力各不相同。

美國在學術界、生技和製藥領域擁有深厚的專業知識，同時對嚴謹的轉化醫學證據有廣泛的需求。加拿大擁有強大的公共研究能力、疾病建模專長和合作網路。墨西哥正在拓展其在生物醫學領域的能力，並有機會加強標準化設施、培訓和跨境夥伴關係。巴西在學術界和公共衛生領域擁有豐富的專業知識，尤其是在感染疾病、熱帶疾病和慢性病方面，但確保基礎設施的一致性仍然至關重要。

行業領導者應該建立證據組合，而不是孤立的小鼠研究。

領導者應先制定以決策為導向的模型策略。這意味著在選擇譜系或平台之前，必須明確定義生物學挑戰、轉換終點、目標群體和失敗標準。如果單一系統無法代表人類的異質性，則應採用互補模型，並預先定義如何將結果與人類細胞、類器官、藥物動力學、生物標記和計算分析結合。

調查方法結合了系統化的二手證據和轉化解釋。

本執行摘要基於明確的市場範圍（用於藥物篩檢和評估的小鼠模型）執行摘要，重點關注應用需求、模型類型、研究流程、技術應用、法規、倫理和區域能力。該評估整合了臨床前藥理學、毒理學、實驗動物科學、轉化醫學、資料管治和可重複性研究等領域的現有原則。

下一個優勢將來自於更好的轉化研究、可重複性和整合性。

小鼠模型將繼續在連接分子層次假說與整個機體的藥理學、安全性和疾病生物學方面發揮關鍵作用。其未來的有效性不在於使用更多模型，而是選擇合適的模型、測量適當的終點指標，並認知到小鼠生物學並不能反映人類疾病。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：用於藥物發現篩檢和評估的小鼠模型市場：按產品類型分類

  • 消耗品
    • 拋棄式產品
    • 試劑盒和檢測方法
    • 培養基和試劑
  • 裝置
  • 軟體和服務

第8章：用於藥物發現篩檢和評估的小鼠模型市場：按模型類型分類

  • 基因改造
    • CRISPR/Cas9
    • 敲門
    • 昏死
    • 基因改造
  • 人性化
  • 有關的
  • 異種移植模型

第9章：用於藥物篩檢和評估的小鼠模型市場：依動物種類分類

  • 體感裸體
  • BALB/c
  • C57BL/6
  • SCID

第10章：用於藥物發現篩檢和評價的小鼠模型市場：按應用領域分類

  • 心血管疾病
  • 中樞神經系統疾病
  • 感染疾病
  • 代謝性疾病
  • 腫瘤學

第11章：用於藥物發現篩檢和評估的小鼠模型市場：按最終用戶分類

  • 學術研究機構
  • CRO
  • 製藥和生物技術公司

第12章：藥物發現篩檢與評估用小鼠模型市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：用於藥物發現篩檢和評價的小鼠模型市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 藥物發現篩檢與評價用小鼠模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Applied StemCell, Inc.
  • Beijing Vitalstar Biotechnology Co., Ltd.
  • Biocytogen Pharmaceuticals（Beijing）Co., Ltd.
  • BioIVT, Inc
  • Charles River Laboratories International, Inc.
  • Crown Bioscience International, Inc.
  • Cyagen Biosciences, Inc.
  • Envigo, Inc.
  • GemPharmatech Co., Ltd.
  • genOway SAS
  • Horizon Discovery Group Limited
  • Ingenious Targeting Laboratory, Inc.
  • Inotiv, Inc.
  • Janvier Labs
  • MD Anderson Cancer Center
  • Oriental BioService, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • SAGE Labs, Inc.
  • Shanghai Biomodel Organism Science & Technology Development Co., Ltd.
  • Shanghai Model Organisms Center, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Transgenic, Inc.
  • University of California, Davis
  • Yecuris, Inc.

第17章 主要專家

Product Code: MRR-537DB9F44B29

The Mouse Model for Drug Screening & Evaluation Market is projected to grow by USD 1,198.64 million at a CAGR of 7.32% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 730.88 million
Estimated Year [2026] USD 784.60 million
Forecast Year [2032] USD 1,198.64 million
CAGR (%) 7.32%

Mouse Models Anchor Translational Drug Screening and Evaluation

Mouse models remain a foundational tool for evaluating pharmacology, toxicology, efficacy, disease mechanisms, and biomarker relationships before human studies. Their value comes from combining controlled genetics and environments with measurable physiological and behavioral endpoints. However, findings must be interpreted alongside species differences, model-specific limitations, and complementary human-relevant methods. Effective programs increasingly position mouse studies within integrated evidence packages rather than treating them as standalone validation.

Demand is shaped by therapeutic complexity, regulatory expectations, reproducibility requirements, and the need to identify safety or efficacy risks earlier. Standardized protocols, rigorous controls, transparent reporting, and careful model selection are therefore central to credible decision-making. Applications span oncology, immunology, infectious disease, neuroscience, metabolic disorders, and rare diseases, with approaches ranging from conventional strains to genetically engineered, humanized, and patient-derived models.

Translational Rigor and Model Diversity Are Reshaping Preclinical Research

The landscape is shifting from broad reliance on traditional inbred strains toward fit-for-purpose model portfolios. Genetically engineered mice, humanized systems, immunocompromised hosts, patient-derived xenografts, and models incorporating sex, age, and comorbidity diversity can address questions that conventional designs may not capture. At the same time, improved study registration, randomization, blinding, power calculations, and independent replication are raising expectations for reproducibility.

Ethical governance is also becoming more consequential. The principles of replacement, reduction, and refinement encourage researchers to limit animal use while improving welfare and information yield. Imaging, longitudinal sampling, microsampling, organoid comparisons, and computational analysis can help extract more data from each study. These changes favor organizations that connect model selection, experimental design, data quality, and translational interpretation from the outset.

Artificial Intelligence Accelerates Design, Analysis, and Translational Interpretation

Artificial intelligence is increasingly applied to select experimental models, prioritize compounds, analyze images, classify phenotypes, and identify relationships across multimodal datasets. Computer vision can support more consistent assessment of tumor burden, tissue pathology, movement, behavior, and cellular responses, while machine-learning workflows can integrate molecular, clinical, and preclinical information to improve hypothesis generation.

The strongest value arises when AI augments-not replaces-experimental judgment. Training-data quality, annotation consistency, external validation, explainability, and bias control remain essential. Models developed from narrow strain, sex, laboratory, or disease datasets may perform poorly when transferred elsewhere. Leaders should establish governance covering data provenance, version control, model performance, human review, and reproducibility, while using AI to reduce avoidable variability and prioritize the most informative studies.

Regional Priorities Reflect Different Research Infrastructures and Regulatory Contexts

In North America, sophisticated biomedical infrastructure, translational partnerships, and strong emphasis on reproducibility support advanced genetically engineered, humanized, imaging, and data-rich mouse studies. Latin America is shaped by uneven access to specialized facilities, growing academic and public-sector research capacity, and the importance of scalable protocols, local disease priorities, and collaborative platforms.

Europe combines substantial pharmaceutical and academic capability with strong animal-welfare expectations, harmonized regulatory principles, and continued interest in alternatives and refinement. The Middle East is developing biomedical research capacity through investment in health science, precision medicine, and specialized facilities, while workforce development and cross-border collaboration remain important. Africa presents opportunities tied to infectious disease, neglected conditions, and locally relevant translational research, alongside infrastructure, funding, and access constraints. Asia-Pacific includes highly advanced research ecosystems as well as rapidly developing markets, with priorities spanning oncology, immunology, metabolic disease, infectious disease, and precision medicine. Across all regions, quality systems, skilled personnel, and interoperable data practices determine whether mouse-model findings translate effectively.

International Groups Shape Collaboration, Standards, and Research Access

The ASEAN countries can benefit from shared infrastructure, harmonized training, and regional study networks that address infectious disease, metabolic health, and locally relevant conditions. BRICS collaboration can broaden access to capabilities, strengthen comparative research, and support model development for diverse populations, provided that data standards and ethical oversight are aligned.

The European Union emphasizes coordinated regulation, animal-welfare safeguards, and alternatives-oriented innovation. The G7 provides a platform for advanced research cooperation, biosecurity dialogue, and reproducibility practices. The GCC is investing in biomedical capacity and can accelerate specialized preclinical research through coordinated facilities and international partnerships. NATO members and associated research networks have particular incentives to strengthen preparedness for infectious disease, biological threats, and medical countermeasure development while maintaining strict governance and responsible-use controls.

Country Capabilities Differ in Scale, Specialization, and Translational Priorities

The United States combines deep academic, biotechnology, and pharmaceutical capabilities with extensive demand for rigorous translational evidence. Canada contributes strong public research, disease-model expertise, and collaborative networks. Mexico is expanding biomedical capacity, with opportunities to strengthen standardized facilities, training, and cross-border partnerships. Brazil has substantial academic and public-health expertise, particularly for infectious, tropical, and chronic diseases, while infrastructure consistency remains important.

In Europe, France, Germany, Italy, Spain, and the United Kingdom support diverse preclinical programs within demanding welfare, quality, and regulatory environments. Russia retains expertise in biomedical research but faces constraints related to international access, collaboration, and supply continuity. In Asia, China, Japan, South Korea, India, and Australia offer distinct strengths: China in scale and model development; Japan in advanced biomedical research and aging-related science; South Korea in biotechnology and translational innovation; India in expanding research capacity and disease-focused programs; and Australia in high-quality biomedical science, infectious-disease research, and strong institutional governance. Country-level execution depends on facility standards, talent, procurement, regulatory clarity, and access to validated model systems.

Industry Leaders Should Build Evidence Portfolios, Not Isolated Mouse Studies

Leaders should begin with a decision-oriented model strategy: define the biological question, translational endpoint, target population, and failure criteria before selecting a strain or platform. Use complementary models when one system cannot represent human heterogeneity, and predefine how results will be integrated with human cells, organoids, pharmacokinetics, biomarkers, and computational analyses.

Invest in reproducibility through randomization, blinding, appropriate controls, preregistered protocols where suitable, power analysis, independent replication, and transparent reporting. Establish digital data standards that preserve metadata, images, sample lineage, and analytical decisions. Apply AI selectively with documented validation and human oversight. Finally, strengthen partnerships with accredited facilities and specialist laboratories, maintain contingency plans for animals and critical reagents, and measure programs by decision quality, translational relevance, welfare performance, and time saved-not by study volume alone.

Methodology Combines Structured Secondary Evidence With Translational Interpretation

This executive summary uses the defined market scope-mouse models used for drug screening and evaluation-and organizes analysis around application needs, model types, research workflows, technology adoption, regulation, ethics, and geographic capability. The assessment integrates established principles from preclinical pharmacology, toxicology, laboratory-animal science, translational medicine, data governance, and reproducibility research.

Insights are synthesized comparatively across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific; ASEAN, BRICS, the European Union, G7, GCC, and NATO; and the specified countries. Because the scope excludes estimates, sizing, shares, forecasts, and company profiling, conclusions focus on verified structural drivers, operational requirements, regional characteristics, and evidence-quality considerations. Interpretations should be updated as regulations, technologies, disease priorities, and institutional capabilities change.

The Next Advantage Will Come From Better Translation, Reproducibility, and Integration

Mouse models will remain important because they connect molecular hypotheses with whole-organism pharmacology, safety, and disease biology. Their future effectiveness will depend less on using more models and more on selecting the right model, measuring the right endpoints, and acknowledging where mouse biology does not represent human disease.

Organizations that combine rigorous experimental design, welfare-conscious practice, AI-enabled analysis, complementary human-relevant systems, and transparent data workflows will be better positioned to make reliable development decisions. Regional and international collaboration can further improve access, standardization, and preparedness. The central strategic priority is an integrated translational framework in which mouse evidence is credible, reproducible, appropriately qualified, and connected to the human questions that ultimately determine therapeutic value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Mouse Model for Drug Screening & Evaluation Market, by Product Type

  • 7.1. Introduction
  • 7.2. Consumables
    • 7.2.1. Disposables
    • 7.2.2. Kits & Assays
    • 7.2.3. Media & Reagents
  • 7.3. Instruments
  • 7.4. Software & Services

8. Mouse Model for Drug Screening & Evaluation Market, by Model Type

  • 8.1. Introduction
  • 8.2. Genetically Engineered
    • 8.2.1. CRISPR/Cas9
    • 8.2.2. Knockin
    • 8.2.3. Knockout
    • 8.2.4. Transgenic
  • 8.3. Humanized
  • 8.4. Syngeneic
  • 8.5. Xenograft

9. Mouse Model for Drug Screening & Evaluation Market, by Animal Species

  • 9.1. Introduction
  • 9.2. Athymic Nude
  • 9.3. BALB/c
  • 9.4. C57BL/6
  • 9.5. SCID

10. Mouse Model for Drug Screening & Evaluation Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. CNS Disorders
  • 10.4. Infectious Diseases
  • 10.5. Metabolic Disorders
  • 10.6. Oncology

11. Mouse Model for Drug Screening & Evaluation Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. CROs
  • 11.4. Pharmaceutical & Biotech Companies

12. Mouse Model for Drug Screening & Evaluation Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Mouse Model for Drug Screening & Evaluation Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Mouse Model for Drug Screening & Evaluation Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Applied StemCell, Inc.
  • 16.2. Beijing Vitalstar Biotechnology Co., Ltd.
  • 16.3. Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
  • 16.4. BioIVT, Inc
  • 16.5. Charles River Laboratories International, Inc.
  • 16.6. Crown Bioscience International, Inc.
  • 16.7. Cyagen Biosciences, Inc.
  • 16.8. Envigo, Inc.
  • 16.9. GemPharmatech Co., Ltd.
  • 16.10. genOway SAS
  • 16.11. Horizon Discovery Group Limited
  • 16.12. Ingenious Targeting Laboratory, Inc.
  • 16.13. Inotiv, Inc.
  • 16.14. Janvier Labs
  • 16.15. MD Anderson Cancer Center
  • 16.16. Oriental BioService, Inc.
  • 16.17. Regeneron Pharmaceuticals, Inc.
  • 16.18. SAGE Labs, Inc.
  • 16.19. Shanghai Biomodel Organism Science & Technology Development Co., Ltd.
  • 16.20. Shanghai Model Organisms Center, Inc.
  • 16.21. Taconic Biosciences, Inc.
  • 16.22. The Jackson Laboratory
  • 16.23. Transgenic, Inc.
  • 16.24. University of California, Davis
  • 16.25. Yecuris, Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Mouse Model for Drug Screening & Evaluation Market, Years Considered for the Study
  • FIGURE 2. Global Mouse Model for Drug Screening & Evaluation Market, Research Design
  • FIGURE 3. Global Mouse Model for Drug Screening & Evaluation Market, Research Framework
  • FIGURE 4. Global Mouse Model for Drug Screening & Evaluation Market, Data Triangulation
  • FIGURE 5. Global Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2025 vs 2032 (%)
  • FIGURE 11. Global Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Mouse Model for Drug Screening & Evaluation Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Mouse Model for Drug Screening & Evaluation Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Mouse Model for Drug Screening & Evaluation Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Mouse Model for Drug Screening & Evaluation Market Segmentation & Coverage
  • TABLE 2. Global Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Consumables Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Consumables Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Consumables Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Disposables Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Disposables Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Disposables Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Kits & Assays Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Kits & Assays Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Kits & Assays Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Media & Reagents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Media & Reagents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Media & Reagents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Software & Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Software & Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Software & Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 23. Global Genetically Engineered Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Genetically Engineered Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Genetically Engineered Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global CRISPR/Cas9 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global CRISPR/Cas9 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global CRISPR/Cas9 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Knockin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Knockin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Knockin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Knockout Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Knockout Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Knockout Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Transgenic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Transgenic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Transgenic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Humanized Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Humanized Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Humanized Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Syngeneic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Syngeneic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Syngeneic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Xenograft Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Xenograft Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Xenograft Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 48. Global Athymic Nude Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Athymic Nude Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Athymic Nude Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global BALB/c Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global BALB/c Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global BALB/c Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global C57BL/6 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global C57BL/6 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global C57BL/6 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global SCID Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global SCID Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global SCID Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 61. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global CNS Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global CNS Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global CNS Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 77. Global Academic & Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Academic & Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Academic & Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global CROs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global CROs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global CROs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Pharmaceutical & Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Pharmaceutical & Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Pharmaceutical & Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 95. North America Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. North America Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 97. North America Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 98. North America Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 99. North America Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 100. North America Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 101. North America Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 102. North America Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 103. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 105. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 106. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 107. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 108. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 109. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 110. Latin America Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 111. Europe Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 112. Europe Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 113. Europe Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 114. Europe Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 115. Europe Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 116. Europe Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 117. Europe Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 118. Europe Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 119. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 120. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 121. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 122. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 123. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 124. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 125. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 126. Middle East Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 127. Africa Mouse Model for Drug Screening & Evaluation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Africa Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 129. Africa Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 130. Africa Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 131. Africa Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 132. Africa Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 133. Africa Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 134. Africa Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. Global Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 136. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 138. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 139. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 140. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 141. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 142. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 143. ASEAN Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 144. GCC Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 145. GCC Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 146. GCC Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 147. GCC Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 148. GCC Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 149. GCC Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 150. GCC Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 151. GCC Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 152. European Union Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. European Union Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 154. European Union Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 155. European Union Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 156. European Union Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 157. European Union Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 158. European Union Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 159. European Union Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 160. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 161. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 162. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 163. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 164. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 165. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 166. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 167. BRICS Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 168. G7 Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 169. G7 Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 170. G7 Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 171. G7 Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 172. G7 Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 173. G7 Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 174. G7 Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 175. G7 Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 176. NATO Mouse Model for Drug Screening & Evaluation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 177. NATO Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 178. NATO Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 179. NATO Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 180. NATO Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 181. NATO Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 182. NATO Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 183. NATO Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 184. Global Mouse Model for Drug Screening & Evaluation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 185. United States Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 186. United States Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 187. United States Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 188. United States Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 189. United States Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 190. United States Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 191. United States Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 192. United States Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. Canada Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 194. Canada Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 195. Canada Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 196. Canada Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 197. Canada Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 198. Canada Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 199. Canada Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 200. Canada Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 201. Mexico Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 202. Mexico Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 203. Mexico Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 204. Mexico Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 205. Mexico Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 206. Mexico Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 207. Mexico Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 208. Mexico Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 209. Brazil Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 210. Brazil Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 211. Brazil Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 212. Brazil Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 213. Brazil Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 214. Brazil Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 215. Brazil Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. Brazil Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 217. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 218. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 219. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 220. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 221. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 222. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 223. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 224. United Kingdom Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 225. Germany Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 226. Germany Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 227. Germany Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 228. Germany Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 229. Germany Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 230. Germany Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 231. Germany Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 232. Germany Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 233. France Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 234. France Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 235. France Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 236. France Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 237. France Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 238. France Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 239. France Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 240. France Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 241. Russia Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 242. Russia Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 243. Russia Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 244. Russia Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 245. Russia Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 246. Russia Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 247. Russia Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 248. Russia Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 249. Italy Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 250. Italy Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 251. Italy Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 252. Italy Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 253. Italy Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 254. Italy Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 255. Italy Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 256. Italy Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 257. Spain Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 258. Spain Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 259. Spain Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 260. Spain Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 261. Spain Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 262. Spain Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 263. Spain Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 264. Spain Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 265. China Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 266. China Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 267. China Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 268. China Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 269. China Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 270. China Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 271. China Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 272. China Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 273. India Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 274. India Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 275. India Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 276. India Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 277. India Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 278. India Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 279. India Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 280. India Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 281. Japan Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 282. Japan Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 283. Japan Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 284. Japan Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 285. Japan Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 286. Japan Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 287. Japan Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 288. Japan Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 289. Australia Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 290. Australia Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 291. Australia Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 292. Australia Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 293. Australia Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 294. Australia Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 295. Australia Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 296. Australia Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 297. South Korea Mouse Model for Drug Screening & Evaluation Market Size, 2017-2032 (USD Million)
  • TABLE 298. South Korea Mouse Model for Drug Screening & Evaluation Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 299. South Korea Mouse Model for Drug Screening & Evaluation Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 300. South Korea Mouse Model for Drug Screening & Evaluation Market Size, by Model Type, 2017-2032 (USD Million)
  • TABLE 301. South Korea Mouse Model for Drug Screening & Evaluation Market Size, by Genetically Engineered, 2017-2032 (USD Million)
  • TABLE 302. South Korea Mouse Model for Drug Screening & Evaluation Market Size, by Animal Species, 2017-2032 (USD Million)
  • TABLE 303. South Korea Mouse Model for Drug Screening & Evaluation Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 304. South Korea Mouse Model for Drug Screening & Evaluation Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 305. Global Mouse Model for Drug Screening & Evaluation Market Share, by Key Player, 2025
  • TABLE 306. Global Mouse Model for Drug Screening & Evaluation Market, Key Experts